Renal Cell Carcinoma

Tivozanib at 1.34 mg showed greater antitumor activity than 0.89 mg, with similar hypertension rates, in kidney cancer.

Lenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.

Tivozanib plus nivolumab had similar patient-reported outcomes to tivozanib alone in advanced kidney cancer after prior treatment, according to the TiNivo-2 study.

Belzutifan plus cabozantinib maintained durable antitumor activity in advanced clear cell renal cell carcinoma, per phase 3 LITESPARK-003 data.

Cabozantinib plus nivolumab and ipilimumab maintained a progression-free survival benefit at 45 months vs placebo in advanced kidney cancer.

Nivolumab plus cabozantinib improved long-term efficacy and safety vs sunitinib in advanced renal cell carcinoma, per final CheckMate 9ER trial results.

Lenvatinib plus belzutifan showed durable activity and a consistent safety profile in advanced clear cell renal cell carcinoma after prior treatment.

During a Case-Based Roundtable® event, Neeraj Agarwal, MD, and participants discussed how they might determine which combination therapy to use for a patient with metastatic renal cell carcinoma.

During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on sequencing targeted therapies.

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal cell carcinoma.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date set for May 26, 2025.

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants depending on their own practice and trial data for a patient with clear cell renal cell carcinoma.

Updated overall survival data from KEYNOTE-564 showed adjuvant pembrolizumab benefits in clear cell renal cell carcinoma, but some patients remain unresponsive.

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients with favorable-risk vs intermediate- or high-risk RCC, and how it changes their treatment options.

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial showing high accuracy for ccRCC detection.

In an interview with Targeted Oncology, Jaime Merchan, MD, delved into data from the LITESPARK-013 trial evaluating belzutifan for advanced clear cell renal cell carcinoma treatment.

During a Case-Based Roundtable® event, Daniel J. George, MD and participants discussed combination regimens for intermediate and poor-risk renal cell carcinoma.

During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old patient with lung-metastatic renal cell carcinoma.

ALLO-316 demonstrated a 50% overall response rate and 33% complete response rate in CD70-positive advanced RCC in the phase 1 TRAVERSE trial.

Casdatifan showed notable clinical activity and an acceptable safety profile in treating patients with metastatic clear cell renal cell carcinoma.

Nazli Dizman, MD, discussed the current measures for enforcing ASCO’s language of respect guidelines in the renal cell carcinoma space.

Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear cell renal cell carcinoma treatment.

During a Case-Based Roundtable® event, Bradley McGregor, MD, moderated a discussion on prognosis and treatment approaches for a patient with stage IV papillary renal cell carcinoma.

During separate virtual live events, David A. Braun, MD, PhD, and Rana R. McKay, MD, surveyed oncologists on options for a patient with clear cell renal cell carcinoma (RCC) in the front line.

During a Case-Based Roundtable® event, Chandler Park, MD, moderated a discussion on how recent trial data and sites of metastasis affect treatment of favorable-risk metastatic clear cell renal cell carcinoma in the second article of a 2-part series.

Jaime Merchan, MD, discusses what the potential clinical implications or takeaways for colleagues are based on findings from the phase 3 CLEAR study in advanced renal cell carcinoma (RCC).

Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.

Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combinations for first-line treatment of metastatic renal cell carcinoma, considering key factors that influence their decision-making process and drawing insights from recent clinical trials such as CheckMate 9ER, KEYNOTE-426, and CLEAR.

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.